Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis - Report - MDSpire
Advertisement
Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis
Clinical Report: Evaluation of Withdrawal Versus Maintenance of IL Inhibitors in Psoriasis
Overview
This systematic review and network meta-analysis indicates that planned withdrawal of anti-interleukin therapy in psoriasis patients generally leads to inferior remission maintenance compared to ongoing therapy, without a reduction in adverse event rates. Notably, bimekizumab and guselkumab demonstrated superior outcomes for PASI 90 endpoints upon withdrawal.
Background
Psoriasis is a chronic immune-mediated condition affecting 2-3% of the global population, with biologics becoming the standard treatment. The decision to withdraw biologic therapy raises concerns about relapse and the need for updated clinical guidance, particularly for patients requiring temporary cessation for reasons such as live vaccinations or pregnancy.
Data Highlights
No new numerical data was presented in the article.
Key Findings
Planned withdrawal of anti-IL therapy is associated with inferior remission maintenance compared to continuous therapy.
No reduction in adverse event rates was observed with withdrawal.
Bimekizumab and guselkumab showed superior PASI 90 outcomes compared to other anti-IL therapies.
Key considerations for withdrawal include drug half-life, timing of relapse, and patient-specific factors.
Structured clinical pathways are essential for managing biologic therapy interruptions.
Clinical Implications
Clinicians should carefully assess the risks of planned withdrawal of anti-IL therapies in psoriasis patients, as it may lead to relapse without reducing adverse events. Continuous maintenance therapy is generally recommended to ensure sustained remission.
Conclusion
The findings underscore the importance of ongoing maintenance therapy for psoriasis patients on anti-IL biologics, particularly in the context of planned withdrawals for clinical reasons.
